Quality Assurance : Fill Finish, Biosimilars, Insulin: IPQA, QMS, Audit and Compliance, AQA.
Quality Control : Microbiology, Insulin: HPLC,UPLC, Analytical Techniques, Sampling, Environmental Monitoring, Water Testing
DP Fill Finish:- Aseptic Manufacturing: Vial Washing, Filling, PFS & Sealing, QMS
DP Medical Device and Packing & Visual Inspection: Labelling, Cartoning, Pick & Place Robotic Machines Handling & Track & Trace.
DS Biosimilars: Upstream and Downstream: Mammalian & Microbial, QMS
Engineering and Maintenance: Automation & Instrumentation, Maintenance, QMS
Requirements :
2 – 10 years of experience in the above-mentioned skill set
Qualification Required: M.Pharm, B.Pharm, MSc(Chemistry, Microbiology, Biotechnology), BSc, Diploma, B.Tech (Electrical, Mechanical, Instrumentation and Automation)
Walk-In-Interview Date : 9th June 2024
Time : 8 AM Onwards
Venue : Biocon House: Hosur Rd, Phase 2, Electronic City, Bengaluru, Karnataka 560100
Interested candidates may also email their resume to:
Quality : varsha.m102@biocon.com
Manufacturing: ananthakrishna.b101@biocon.com and jyothirmai.mondi101@biocon.com
A global leader As we search for cutting-edge ways to improve patient outcomes now in order to create a brighter future, we continue to use the pioneering spirit that paved the way for biotechnology in India. This spurs us to continuously investigate new methods for treating cancer, diabetes, and autoimmune diseases. Through our pharmaceuticals, millions of patients are given access to life-saving care and relief in more than 120 countries, and our research and development is focused on prevention, alleviation, and treatment. Our aim is to attain health parity. With the aid of state-of-the-art therapeutic platforms, our 13,500+ employees blend compassion, science, and creativity to solve problems in healthcare. Our four global businesses are biologics that are novel, biosimilars, research services, and generics.
They are indicative of Biocon's risk-aware approach, which is bolstered by adaptable network connections, a robust pipeline, and a timely "developing markets" emphasis. We have leveraged India's value advantage of unparalleled scientific competence and cost-competitive manufacturing to achieve size, speed, and quality. By enabling more patient access to pharmaceuticals globally, we want to create health equity. Our goal is to provide an affordable specialist pharmaceutical portfolio to all individuals, regardless of location. We are still investing in the development of novel therapies for cancer, diabetes, and immunology. Our scale economies and global reach are expanding.